SCM
IKT icon

Squadron Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Squadron Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.09M Sell
3,000,000
-500,000
-14% -$895K 1.89% 15
2026
Q1 		$5.88M Sell
3,500,000
-725,000
-17% -$1.29M 2.15% 15
2025
Q4 		$8.66M Buy
+4,225,000
New +$6.72M 3.67% 8

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squadron Capital Management's IKT Position: Q2 2026 in Review

Squadron Capital Management reduced its Inhibikase Therapeutics (IKT) stake by 14% in Q2 2026, selling an estimated $895K and leaving 3,000,000 shares worth $6.09M. The position accounts for 1.89% of the portfolio, ranked #15.

Squadron Capital Management first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.66M in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Squadron Capital Management held 3,000,000 shares of Inhibikase Therapeutics worth $6.09M as of Q2 2026.
  • Squadron Capital Management sold 500,000 Inhibikase Therapeutics shares in Q2 2026, an estimated $895K.
  • Inhibikase Therapeutics made up 1.89% of Squadron Capital Management's portfolio in Q2 2026, its #15 holding.
  • Squadron Capital Management first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Squadron Capital Management's Inhibikase Therapeutics position peaked at $8.66M in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.